UNSPSC 41151622: Plasma oncometer for clinical use

In this classification a plasma oncometer for clinical use is a device intended to measure plasma oncotic pressure, which is that portion of the total plasma osmotic pressure contributed by protein and other molecules too large to pass through a specified semipermeable membrane. Because variations in plasma oncotic pressure are indications of certain disorders, measurements of the variations are useful in the diagnosis and treatment of these disorders US FDA regulates Plasma oncometer for clinical use under 21 CFR 862.2720 and under FDA product code JJK.

UNSPSC 41151622 Plasma oncometer for clinical use is a Commodity code, but the recent state and local contract opportunities tagged under this code show little relevant activity. The opportunities posted between March and July 2026 span timeclock equipment (Mississippi State University sealed bid, July 2026), hydrogen generator supplies (City of Philadelphia micro purchase, July 2026), fire alarm system components (Mississippi State University sole source, July 2026), spectrometer instruments (Mississippi State University sole source, July 2026), water testing reagents (Texas Health and Human Services Commission, July 2026), X-ray anode equipment (State of Oregon sole source, June 2026), early childhood learning materials (Mississippi State University sole source, June 2026), and numerous other procurements across laboratory analysis systems, educational resources, agricultural equipment, and specialized research instruments. None of these opportunities involve plasma oncometers or clinical oncology equipment of any kind. The code appears to have been assigned to these diverse solicitations in error or through a data classification mismatch, as the actual scope of work being procured—from educational toys to laboratory analytical instruments to transit shelter structures—bears no relationship to the code's nominal scope of clinical plasma measurement devices. State and local procurement activity under this code shows no meaningful opportunities for plasma oncometer vendors.